A carregar...
Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial
PURPOSE: We hypothesized that the addition of gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, to docetaxel would enhance therapeutic efficacy in squamous cell carcinoma of the head and neck (SCCHN). PATIENTS AND METHODS: Patients with recurrent or metastatic SCCHN wi...
Na minha lista:
| Main Authors: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Clinical Oncology
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3612594/ https://ncbi.nlm.nih.gov/pubmed/23460714 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.45.4272 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|